Randomised clinical trial: tegoprazan, a novel potassium‐competitive acid blocker, or lansoprazole in the treatment of gastric ulcer
Alimentary Pharmacology & Therapeutics2020Vol. 52(5), pp. 789–797
Citations Over TimeTop 10% of 2020 papers
Yu Kyung Cho, Myung‐Gyu Choi, Suck Chei Choi, Kee Myung Lee, Tae Oh Kim, Soo‐Heon Park, Jeong Seop Moon, Yun Jeong Lim, Dae Hwan Kang, Gab Jin Cheon, Gwang Ho Baik, Kyoung Oh Kim, Kwang Bum Cho, Jin Seok Jang, Jong‐Jae Park, Byoung Kwan Son, Hye‐Kyung Jung, Byung‐Wook Kim, Sung Kuk Kim, Soo Teik Lee, Jae Myung, Ah Rong Kim, Eun Ji Kim, Hyun Wook Park, Geun Seog Song
Abstract
Tegoprazan 50 or 100 mg were not inferior to lansoprazole 30 mg once daily in the treatment of gastric ulcers.
Related Papers
- → Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: A comparison between two different daily doses of lansoprazole(2006)66 cited
- → Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole(2004)44 cited
- → Dose ranging study of lansoprazole, a new proton pump inhibitor, in patients with high gastric acid secretion(1992)10 cited
- → ▼Lansoprazole - another proton pump inhibitor(1995)6 cited